GNE-8025
GNE-8025 is an orally active pan-TEAD transcription factor inhibitor, with IC50 values of 45, 38, 1035 and 24 nM against TEAD1, TEAD2, TEAD3 and TEAD4, respectively. GNE-8025 allosterically disrupts the TEAD-YAP/TAZ interaction and inhibits TEAD-mediated oncogenic transcriptional programs via the Hippo signaling pathway. GNE-8025 suppresses YAP-driven tumor cell growth. GNE-8025 enhances the activity of MAPK and KRASG12C inhibitors. GNE-8025 can be used for the research of pleural mesothelioma and KRASG12C-mutant cancers.
For research use only. We do not sell to patients.
- CAS No.: 2933893-27-5
- Formula: C19H17F3N4O4
- Molecular Weight:422.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
GNE-8025 (overnight) potently inhibits the binding of YAP to purified TEAD1, TEAD2 and TEAD4 proteins, with IC50 values of 5, 8 and 37 nM, respectively, while it shows weak inhibitory activity against TEAD3 (IC50 = 0.326 μM)[1].
GNE-8025 (6 days) potently inhibits the proliferation of Hippo pathway-dependent mesothelioma cell lines NCI-H226 (EC50 = 7 nM) and MSTO-211H (EC50 = 22 nM), while exhibits extremely low activity against the Hippo pathway-independent cell line VMRC-LCD (EC50 = 18 μM)[1].
GNE-8025 potently inhibits the proliferation of pleura-derived cancer cell lines, and its sensitivity is highly correlated with the gene expression signatures of YAP/TAZ activation, angiogenesis, and epithelial-mesenchymal transition[1].
GNE-8025 (7-14 days) potently and dose-dependently inhibits colony formation of Hippo pathway-dependent NCI-H226 mesothelioma cells, but has no effect on Hippo pathway-independent ES-2 cells[1].
GNE-8025 (48 h) downregulates the expression of YAP/TAZ target genes and proliferation genes in Hippo pathway-dependent NCI-H226 mesothelioma cells, while exerting minimal effects on Hippo pathway-independent ES-2 cells[1].
GNE-8025 (24 h) downregulates the expression of YAP/TAZ target genes and proliferation genes, and upregulates the expression of apoptosis genes in NF2-deficient mesothelioma cell lines, but exerts no effect on SK-N-FI and VMRC-LCD cells that are independent of the Hippo pathway[1].
GNE-8025 (6 days) enhances the efficacy of RTK and RAS/MAPK pathway inhibitors in various cancer cell lines, exerts synergistic growth inhibitory effects when combined with KRASG12C, EGFR and RAF inhibitors, and reduces cell proliferation and increases cell apoptosis in combination therapy by regulating transcriptional signatures[1].
GNE-8025 (1 μM; 48 h) induces G0/G1 cell cycle arrest in Hippo pathway-dependent NCI-H226 and MSTO-211H mesothelioma cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Hippo-dependent NCI-H226 and MSTO-211H mesothelioma cell lines
-
Concentration:1 μM
-
Incubation Time:48 h
-
Result:Induced a G0/G1 cell cycle arrest in both NCI-H226 and MSTO-211H cells, as shown by reduced EdU-positive (S-phase) cells compared to DMSO control.
Parmacokinetics
In Vivo
GNE-8025 (3-20 mg/kg; p.o.; once daily or twice daily; 21 days) effectively inhibits tumor growth of MSTO-211H mesothelioma xenografts in mouse models[1].
GNE-8025 (1.5-10 mg/kg; p.o.; twice daily; for 21 days) effectively inhibits tumor growth when administered twice daily for 21 days in the PXF1752 mesothelioma patient-derived xenograft mouse model[1].
GNE-8025 (10-20 mg/kg; p.o.; once daily or twice daily; for 21 consecutive days) does not inhibit tumor growth in the Hippo pathway-independent ES-2 ovarian cancer xenograft mouse model, confirming its specificity for tumors with Hippo pathway dysregulation[1].
GNE-8025 (0.5-10 mg/kg; p.o.; twice daily; 20-21 days) significantly enhances the antitumor efficacy of Divarasib in a mouse model of NCI-H2122 KRASG12C-mutant lung adenocarcinoma xenografts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C.B-17 SCID[1]
-
Dosage:0.025, 0.05, 0.1, 0.25, 0.5, 1.5, 5, 10 and 25 and 50 mg/kg
-
Administration:p.o.; daily or twice daily; 4 days or 21 days
-
Result:Achieved dose-proportional decrease in YAP/TAZ target score up to 20 mg/kg daily, with no further improvement at 50 mg/kg daily.
Achieved equivalent YAP/TAZ target score inhibition with 20 mg/kg daily and 10 mg/kg twice daily.
Maintained YAP/TAZ target score for 24 hours post-last dose at 3 mg/kg daily and 50 mg/kg daily, with rebound starting at 31 hours post-dose for 50 mg/kg daily.
Significantly reduced ANKRD1 and CTGF transcript levels with 10 mg/kg twice daily.
Significantly reduced Ki67 and phospho-histone H3 (pHH3) levels with 20 mg/kg daily.
Significantly inhibited tumor growth starting at 1.5 mg/kg twice daily and 10 mg/kg daily in 21-day study, with efficacy plateauing at 20 mg/kg daily or 10 mg/kg twice daily.
Achieved dose-proportional decrease in YAP/TAZ target score starting at 1.5 mg/kg twice daily in PK/PD study, with chromatin accessibility at YAP/TAZ-TEAD binding sites decreasing dose-dependently starting at 1.5 mg/kg twice daily and plateauing at 10 mg/kg twice daily.
Achieved rapid pathway inhibition (within 2 days), with rebound above EC50 threshold at 24 hours post-last dose for 1.5 mg/kg twice daily, and suppression maintained to 31 hours post-last dose for 10 mg/kg twice daily.
-
Animal Model:C.B-17 SCID[1]
-
Dosage:3 mg/kg; 20 mg/kg
-
Administration:p.o.; daily or twice daily; 21 days
-
Result:Demonstrated significant anti-tumor activity in MSTO-211H xenografts.
Caused minimal impact on mouse body weight.
-
Animal Model:Immunocompromised mice[1]
-
Dosage:1.5 mg/kg; 10 mg/kg
-
Administration:p.o.; twice daily; 21 days
-
Result:Demonstrated significant anti-tumor activity in the PXF1752 PDX model.
Caused minimal impact on mouse body weight.
-
Animal Model:C.B-17 SCID[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:p.o.; daily or twice daily; 21 days
-
Result:Showed no response in ES-2 xenografts.
-
Animal Model:Immunocompromised mice[1]
-
Dosage:0.5, 1.5, 2.5 and 10 mg/kg (single agent or combination with Divarasib (HY-145928) 5-50 mg/kg daily)
-
Administration:p.o.; twice daily; 20-21 days
-
Result:Showed minimal anti-tumor activity as single agent, with tumor growth tracking vehicle control.
Dose-dependently enhanced efficacy when combined with Divarasib (25 mg/kg daily), resulting in tumor regression with TGI values ranging from 108% to 121%.
Resulted in tumor regressions across all groups when 10 mg/kg twice daily was combined with Divarasib 5-50 mg/kg daily, with maximum TGI values reaching 127%.
Dose-dependently suppressed YAP/TAZ transcriptional signatures as single agent.
Combination treatment with Divarasib resulted in more profound suppression of both YAP/TAZ and MAPK signatures compared to single agents.
Chemical Information
-
CAS No. 2933893-27-5
-
Molecular Weight 422.36
-
Formula C19H17F3N4O4
-
SMILES
C=CC(NCC1=NN(C2=C1C([C@@H](CO)O)=CC=N2)C3=CC=C(C=C3)OC(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Nuclear Protein Extraction (High-Salt/Hypotonic Fractionation)
The high-salt/hypotonic fractionation method for nuclear protein extraction is based on the differential solubility of cellular components. Cytoplasmic proteins are extracted first using a hypotonic buffer that causes cell swelling and membrane rupture, followed by centrifugation to separate the cytoplasmic supernatant from the nuclear pellet. The nuclear pellet is then subjected to high-salt extraction (e. g. , 0. 4 M (NH4)2SO4 or 1 M NaCl) to solubilize tightly bound nuclear matrix proteins, including transcription factors, histones, and structural proteins associated with chromatin and the nuclear scaffold. This approach allows for the isolation of both soluble cytoplasmic proteins and salt-resistant nuclear proteins while minimizing cross-contamination.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)